CHARLES RIVER LABS INTL INC.

ISIN: US1598641074 WKN: 159864107 Asset Class: Stock



Company Profile

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Financial figures, Fiscal year: from 31.12. to 30.12.						
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Current assets	1,608,662,000		1,439,032,000		1,274,095,000	
Common stock capital		513,000		509,000		505,000
Fixed assets	6,586,339,000		6,163,738,000		5,750,197,000	
Equity capital of a company		3,658,998,000		3,023,505,000		2,591,992,000
Cash and cash equivalents	282,574,000		240,104,000		245,237,000	
Accrued liabilities		0		44,100,000		148,001,000
Other assets	-		-		-	
Current liabilities		1,055,082,000		1,091,585,000		1,033,185,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,480,921,000		3,487,680,000		3,399,115,000
Different income		-		-		-
Other liabilities		223,191,000		130,722,000		94,858,000
Total accets	9 105 001 000	9 105 001 000	7 602 770 000	7 602 770 000	7 024 202 000	7 024 202 000

Other liabilities		223,191,000		130,722,000		94,858,000
Total assets	8,195,001,000	8,195,001,000	7,602,770,000	7,602,770,000	7,024,292,000	7,024,292,000
Balance notes						
				2023	2022	2021
Accounting standard				US-GAAP	US-GAAP	US-GAAP
Employees				21,800	21,400	20,000
Equity ratio				45.41%	40.39%	37.71%
Debt-equity ratio				120.23%	147.59%	165.15%
Others						
				2023	2022	2021
Tax Expense Rate				17.36%	20.93%	17.03%

CHARLES RIVER LABS INTL INC.

ISIN: US1598641074 WKN: 159864107 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,129,409,000	3,976,060,000	3,540,160,000
Net income	474,624,000	486,226,000	390,982,000
EBIT	664,185,176	681,341,478	547,990,648
Operating income before taxes	581,284,000	622,987,000	480,710,000
Cash Flow	683,898,000	619,640,000	760,799,000
Net interest income	-131,514,000	-108,223,000	-107,389,000
Research and development expenses	-	-	-
Income taxes	100,914,000	130,379,000	81,873,000
Result from investments in subsidaries, associates and other	-	-	0
Revenues per employee	176,504	173,126	164,936

Board of Directors

Members of Management Board			
Craig Thompson	Member of Board of Directors		
Deborah Kochevar	Member of Board of Directors		
Martin MacKay	Member of Board of Directors		
Nancy Andrews	Member of Board of Directors		
George Llado	Member of Board of Directors		
George Massaro	Member of Board of Directors		
Reshema Kemps-Polanco	Member of Board of Directors		
Richard Wallman	Member of Board of Directors		
Robert Bertolini	Member of Board of Directors		
Virginia Wilson	Member of Board of Directors		
James Foster	Chairman of Managing Board		
Birgit Girshick	Member of Executive Committee		
Flavia Pease	Member of Executive Committee		
Gina M. Mullane	Member of Executive Committee		
John C. Ho	Member of Executive Committee		
Julie Frearson	Member of Executive Committee		
Kristen M. Eisenhauer	Member of Executive Committee		
Mark Mintz	Member of Executive Committee		
Matthew L. Daniel	Member of Executive Committee		
Michael G. Knell	Member of Executive Committee		
Victoria L. Creamer	Member of Executive Committee		